PURPOSE: Aphase 1 study of gefitinib in combination with oxaliplatin, 5-fluorouracil and leucovorin (IFOX)was conducted to evaluate the safety and feasibility of this regimen. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated with escalating doses of gefitinib (250 mg or 500 mg once daily) in combination with FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin). The initial dose of oxaliplatin was 70 mg/m2 with sequential dose escalation to 85 mg/m2. RESULTS: Sixteen patients received a total of 138 14-day courses of daily gefitinib in combination with FOLFOX. Escalation of gefitinib from 250 mg/d to 500 mg/d with FOLFOX was well-tolerated. In addition, no severe toxicities precluded subsequent dose escalation of oxaliplatin from 70 mg/m2 to 85 mg/m2 at which no dose-limiting toxicity was seen. No further dose escalation was performed as this represented the oxaliplatin dose administered in the standard FOLFOX-4 regimen. The most predominant toxicity was diarrhea, which was well controlled with oral antidiarrheal agents. Four partial remissions occurred in patients with metastatic colorectal cancer. CONCLUSIONS: Gefitinib as a 500 mg daily continuous dose was well tolerated in combination with full doses of FOLFOX-4.
PURPOSE: Aphase 1 study of gefitinib in combination with oxaliplatin, 5-fluorouracil and leucovorin (IFOX)was conducted to evaluate the safety and feasibility of this regimen. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated with escalating doses of gefitinib (250 mg or 500 mg once daily) in combination with FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin). The initial dose of oxaliplatin was 70 mg/m2 with sequential dose escalation to 85 mg/m2. RESULTS: Sixteen patients received a total of 138 14-day courses of daily gefitinib in combination with FOLFOX. Escalation of gefitinib from 250 mg/d to 500 mg/d with FOLFOX was well-tolerated. In addition, no severe toxicities precluded subsequent dose escalation of oxaliplatin from 70 mg/m2 to 85 mg/m2 at which no dose-limiting toxicity was seen. No further dose escalation was performed as this represented the oxaliplatin dose administered in the standard FOLFOX-4 regimen. The most predominant toxicity was diarrhea, which was well controlled with oral antidiarrheal agents. Four partial remissions occurred in patients with metastatic colorectal cancer. CONCLUSIONS:Gefitinib as a 500 mg daily continuous dose was well tolerated in combination with full doses of FOLFOX-4.
Authors: K Inoue; J W Slaton; P Perrotte; D W Davis; C J Bruns; D J Hicklin; D J McConkey; P Sweeney; R Radinsky; C P Dinney Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2000-05 Impact factor: 12.531
Authors: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem Journal: N Engl J Med Date: 2004-07-22 Impact factor: 91.245
Authors: Roy S Herbst; Giuseppe Giaccone; Joan H Schiller; Ronald B Natale; Vincent Miller; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Ira Oliff; James A Reeves; Michael K Wolf; Annetta D Krebs; Steven D Averbuch; Judith S Ochs; John Grous; Abderrahim Fandi; David H Johnson Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: M S Braun; F Adab; C Bradley; K McAdam; G Thomas; N J Wadd; D Rea; R Philips; C Twelves; J Bozzino; C MacMillan; M P Saunders; R Counsell; H Anderson; A McDonald; J Stewart; A Robinson; S Davies; F J Richards; M T Seymour Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: George A Fisher; Timothy Kuo; Meghan Ramsey; Erich Schwartz; Robert V Rouse; Cheryl D Cho; Joanne Halsey; Branimir I Sikic Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Jeffrey A Meyerhardt; Marek Ancukiewicz; Thomas A Abrams; Deborah Schrag; Peter C Enzinger; Jennifer A Chan; Matthew H Kulke; Brian M Wolpin; Michael Goldstein; Lawrence Blaszkowsky; Andrew X Zhu; Meaghan Elliott; Eileen Regan; Rakesh K Jain; Dan G Duda Journal: PLoS One Date: 2012-06-12 Impact factor: 3.240